Results of lamivudine trials in Asia

[Guest guest]

J Hepatol. 2003;39 Suppl 1:S111-5.

Results of lamivudine trials in Asia.

Liaw YF.

Liver Research Unit, Chang Gung Memorial Hospital and Chiang Gung

University, 199 Tung Hwa North Road, Taipei, Taiwan. liveryfl@...

In summary, 100 mg daily lamivudine therapy is safe and effective in Asian

patients in terms of HBV suppression, ALT normalization and improvement in

histology. The complete response rate after 1 year of lamivudine therapy is

only around 15% but increases with increasing duration of treatment and

increasing pretherapy ALT levels. Similar results were observed in patients

with HBeAg-negative chronic hepatitis but published data are limited. YMDD

mutations may emerge after 6-9 months of lamivudine therapy and its

incidence also increases with increasing duration of therapy. The emergence

of YMDD mutations is associated with viral and biochemical breakthrough.

Hepatitis flares, sometimes associated with hepatic decompensation, may

develop after stopping lamivudine therapy and in patients with YMDD

mutations during continuing lamivudine therapy. The benefit of long-term

lamivudine therapy therefore must be weighed carefully against the concern

about YMDD mutations and the durability of therapeutic response. The

development of new strategies, including selection of patient and timing of

therapy, and new drugs are needed to further improve the therapeutic

efficacy.

Publication Types:

Review

Review, Tutorial

PMID: 14708688 [PubMed - indexed for MEDLINE]

[Guest guest]

J Hepatol. 2003;39 Suppl 1:S111-5.

Results of lamivudine trials in Asia.

Liaw YF.

Liver Research Unit, Chang Gung Memorial Hospital and Chiang Gung

University, 199 Tung Hwa North Road, Taipei, Taiwan. liveryfl@...

In summary, 100 mg daily lamivudine therapy is safe and effective in Asian

patients in terms of HBV suppression, ALT normalization and improvement in

histology. The complete response rate after 1 year of lamivudine therapy is

only around 15% but increases with increasing duration of treatment and

increasing pretherapy ALT levels. Similar results were observed in patients

with HBeAg-negative chronic hepatitis but published data are limited. YMDD

mutations may emerge after 6-9 months of lamivudine therapy and its

incidence also increases with increasing duration of therapy. The emergence

of YMDD mutations is associated with viral and biochemical breakthrough.

Hepatitis flares, sometimes associated with hepatic decompensation, may

develop after stopping lamivudine therapy and in patients with YMDD

mutations during continuing lamivudine therapy. The benefit of long-term

lamivudine therapy therefore must be weighed carefully against the concern

about YMDD mutations and the durability of therapeutic response. The

development of new strategies, including selection of patient and timing of

therapy, and new drugs are needed to further improve the therapeutic

efficacy.

Publication Types:

Review

Review, Tutorial

PMID: 14708688 [PubMed - indexed for MEDLINE]

[Guest guest]

J Hepatol. 2003;39 Suppl 1:S111-5.

Results of lamivudine trials in Asia.

Liaw YF.

Liver Research Unit, Chang Gung Memorial Hospital and Chiang Gung

University, 199 Tung Hwa North Road, Taipei, Taiwan. liveryfl@...

In summary, 100 mg daily lamivudine therapy is safe and effective in Asian

patients in terms of HBV suppression, ALT normalization and improvement in

histology. The complete response rate after 1 year of lamivudine therapy is

only around 15% but increases with increasing duration of treatment and

increasing pretherapy ALT levels. Similar results were observed in patients

with HBeAg-negative chronic hepatitis but published data are limited. YMDD

mutations may emerge after 6-9 months of lamivudine therapy and its

incidence also increases with increasing duration of therapy. The emergence

of YMDD mutations is associated with viral and biochemical breakthrough.

Hepatitis flares, sometimes associated with hepatic decompensation, may

develop after stopping lamivudine therapy and in patients with YMDD

mutations during continuing lamivudine therapy. The benefit of long-term

lamivudine therapy therefore must be weighed carefully against the concern

about YMDD mutations and the durability of therapeutic response. The

development of new strategies, including selection of patient and timing of

therapy, and new drugs are needed to further improve the therapeutic

efficacy.

Publication Types:

Review

Review, Tutorial

PMID: 14708688 [PubMed - indexed for MEDLINE]

[Guest guest]

J Hepatol. 2003;39 Suppl 1:S111-5.

Results of lamivudine trials in Asia.

Liaw YF.

Liver Research Unit, Chang Gung Memorial Hospital and Chiang Gung

University, 199 Tung Hwa North Road, Taipei, Taiwan. liveryfl@...

In summary, 100 mg daily lamivudine therapy is safe and effective in Asian

patients in terms of HBV suppression, ALT normalization and improvement in

histology. The complete response rate after 1 year of lamivudine therapy is

only around 15% but increases with increasing duration of treatment and

increasing pretherapy ALT levels. Similar results were observed in patients

with HBeAg-negative chronic hepatitis but published data are limited. YMDD

mutations may emerge after 6-9 months of lamivudine therapy and its

incidence also increases with increasing duration of therapy. The emergence

of YMDD mutations is associated with viral and biochemical breakthrough.

Hepatitis flares, sometimes associated with hepatic decompensation, may

develop after stopping lamivudine therapy and in patients with YMDD

mutations during continuing lamivudine therapy. The benefit of long-term

lamivudine therapy therefore must be weighed carefully against the concern

about YMDD mutations and the durability of therapeutic response. The

development of new strategies, including selection of patient and timing of

therapy, and new drugs are needed to further improve the therapeutic

efficacy.

Publication Types:

Review

Review, Tutorial

PMID: 14708688 [PubMed - indexed for MEDLINE]